美苯妥英
抗惊厥药
药理学
口服
代谢物
微克
药代动力学
活性代谢物
化学
癫痫
医学
内科学
新陈代谢
生物化学
细胞色素P450
精神科
CYP2C19型
体外
作者
W. H. Theodore,M. E. Newmark,Bindu T. Desai,Harvey J. Kupferberg,J. Kiffin Penry,RJ Porter,W. Yonekawa
出处
期刊:Neurology
[Ovid Technologies (Wolters Kluwer)]
日期:1984-08-01
卷期号:34 (8): 1100-1100
被引量:9
标识
DOI:10.1212/wnl.34.8.1100
摘要
We investigated the conversion of mephenytoin to nirvanol in five patients with uncontrolled complex partial seizures. After a 50-mg single oral dose, mean peak mephenytoin level was 0.48 microgram/ml and nirvanol 0.37 microgram/ml. After 400 mg, peak mephenytoin level was 3.9 micrograms/ml and nirvanol 2.5 micrograms/ml. On 400 mg daily, mephenytoin reached a mean steady-state level of 1.5 micrograms/ml. Nirvanol mean steady-state level was 18 micrograms/ml. Mean plasma half-life was 17 hours for mephenytoin and 114 hours for nirvanol. Two patients had reduced seizures during mephenytoin therapy and one a transient increase during drug withdrawal. No toxicity was seen, but mephenytoin was not more effective than phenytoin.
科研通智能强力驱动
Strongly Powered by AbleSci AI